Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Hematologic Oncology Update
00:00
BTK degraders: mechanism and promise
She explains targeted BTK degraders, activity in BTK‑mutant resistant CLL, and early clinical efficacy signals.
Play episode from 12:02
Transcript
